| 11.635 -0.875 (-6.99%) | 04-25 12:26 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 15.74 |
1-year : | 17.16 |
| Resists | First : | 13.47 |
Second : | 14.69 |
| Pivot price | 12.7 |
|||
| Supports | First : | 11.5 |
Second : | 9.56 |
| MAs | MA(5) : | 12.22 |
MA(20) : | 12.86 |
| MA(100) : | 16.66 |
MA(250) : | 19.5 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 24 |
D(3) : | 24.4  |
| RSI | RSI(14): 33.1 |
|||
| 52-week | High : | 30.27 | Low : | 11.5 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NVRO ] has closed below the lower bollinger band by 4.8%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 34.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 13.32 - 13.39 | 13.39 - 13.45 |
| Low: | 12.32 - 12.4 | 12.4 - 12.46 |
| Close: | 12.39 - 12.51 | 12.51 - 12.62 |
Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. It also provides 10 kHz Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was incorporated in 2006 and is headquartered in Redwood City, California.
Thu, 25 Apr 2024
Federated Hermes Inc. Has $9.28 Million Position in Nevro Corp. (NYSE:NVRO) - MarketBeat
Sat, 20 Apr 2024
Nevro (NVRO) Q2 Earnings Lag Estimates, FY23 View Cut - Yahoo Movies UK
Thu, 22 Feb 2024
Why Nevro Stock Lagged the Market on Thursday - The Motley Fool
Wed, 21 Feb 2024
Nevro Corp (NVRO) Reports Modest Revenue Growth Amidst Strategic Shifts - GuruFocus.com
Wed, 21 Feb 2024
Nevro (NVRO) Enters Into Cooperation Agreement With Engaged Capital - StreetInsider.com
Wed, 21 Feb 2024
Nevro Enters Into Cooperation Agreement With Engaged Capital - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 37 (M) |
| Shares Float | 36 (M) |
| Held by Insiders | 3.2 (%) |
| Held by Institutions | 107.8 (%) |
| Shares Short | 4,200 (K) |
| Shares Short P.Month | 4,360 (K) |
| EPS | -2.56 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.06 |
| Profit Margin | -21.7 % |
| Operating Margin | -10.2 % |
| Return on Assets (ttm) | -10.1 % |
| Return on Equity (ttm) | -29.9 % |
| Qtrly Rev. Growth | 2 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 11.59 |
| EBITDA (p.s.) | -2.52 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -59 (M) |
| Levered Free Cash Flow | -22 (M) |
| PE Ratio | -4.5 |
| PEG Ratio | 0 |
| Price to Book value | 1.42 |
| Price to Sales | 0.99 |
| Price to Cash Flow | -7.18 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|